
CLAIMS

[Claim 1]

A compound of the formula (I) or a salt thereof,

[Chem. 1]



(I)

(wherein in the formula,

A is CR^A or N,

R^A is H, optionally substituted C_{1-3} alkyl or cyano,


Q is CR^Q or N,

R^Q is H, halogen, optionally substituted C_{1-3} alkyl, C_{3-6} cycloalkyl or vinyl,

E is CH or N,

R^1 is naphthyl optionally substituted with one or two groups selected from the group consisting of optionally substituted C_{1-3} alkyl, cyano, OH and halogen, or R^1 is a group selected from the group consisting of the formula (II), the formula (III) and the formula (IV) below,

[Chem. 2]



(II) (III) (IV)

R^{1a}, R^{1b} and R^{1c}, which are the same as or different from each other, are H, optionally substituted $C_{1\text{-}3}$ alkyl, vinyl or halogen,


R^2 is $-V^1-V^2$ or W,

V^1 is a bond, $-CH_2-$, -O-, -S- or $-N(R^{V1})-$,

R^{V1} is H or optionally substituted $C_{1\text{-}3}$ alkyl,

V^2 is the formula (V) or the formula (VI) below,


[Chem. 3]



(V) (VI)

W is the formula (VII) or the formula (VII-2) below or 7-membered to 9-membered bridged heterocycloalkyl containing one to two nitrogen atoms,

[Chem. 4]



(VII) (VII-2)

each R^{2a}, which is the same as or different from each other, are OH, OCH_3, F or optionally substituted $C_{1\text{-}3}$ alkyl, where R^{2a} is attached only to a carbon atom that is an atom

forming a ring selected from the group consisting of an azetidine ring represented by the formula (V), a pyrrolidine ring represented by the formula (VI), a piperidine ring represented by the formula (VII) and a piperazine ring represented by the formula (VII-2),

m is an integer of 0 to 2,

R^3 is optionally substituted C_{1-6} alkyl, optionally substituted heterocycloalkyl or optionally substituted heteroaryl,

X is a bond, $-CH_2-$, -O-, -S- or $-NR^{4X}-$,

R^{4X} is H or optionally substituted C_{1-3} alkyl,

Y^1 is -O-(optionally substituted C_{1-3} alkylene)-^{*Y2}, -S-(optionally substituted C_{1-3} alkylene)-^{*Y2}, $-SO_2-$(optionally substituted C_{1-3} alkylene)-^{*Y2}, $-NR^Y-$(optionally substituted C_{1-3} alkylene)-^{*Y2}, -(optionally substituted C_{1-3} alkylene)-O-^{*Y2}, -(optionally substituted C_{1-3} alkylene)-S-^{*Y2}, -(optionally substituted C_{1-3} alkylene)-SO_2-^{*Y2} or -(optionally substituted C_{1-3} alkylene)-NR^Y-^{*Y2} (^{*Y2} represents a linking moiety to Y^2),

R^Y is H or optionally substituted C_{1-3} alkyl,

Y^2 is a bond, optionally substituted phenylene or optionally substituted heteroarylene,

Linker is one group chemically linking Y^2 to EUB, and

EUB is a group capable of binding to one E3 ubiquitin ligase selected from the group consisting of cereblon, IAP, MDM2, DCAF11, DCAF15, DCAF16, BIRC2, KEAP1, RNF4, RNF114, FEM1B and AhR).


[Claim 2]

The compound or a salt thereof according to claim 1, wherein EUB is a group capable of binding to cereblon.

[Claim 3]

The compound or a salt thereof according to claim 2, wherein EUB is the formula (XV) below,

[Chem. 5]



(X V)

G is CR^G or N,


R^G is H or $C_{1\text{-}6}$ alkyl,

Z is one group selected from the group consisting of the formulae (Z-1), (Z-2), (Z-3), (Z-4), (Z-5), (Z-6), (Z-7), (Z-8), (Z-9), (Z-10), (Z-11), (Z-12), (Z-13), (Z-14), (Z-15), (Z-16), (Z-17), (Z-18), (Z-19), (Z-20), (Z-21), (Z-22) and (Z-23) below,


wherein ring B1 and ring B2 in the formulae (Z-1), (Z-2), (Z-3), (Z-4), (Z-5), (Z-6), (Z-7), (Z-8), (Z-9), (Z-10), (Z-11), (Z-12), (Z-13), (Z-14), (Z-15), (Z-16), (Z-17), (Z-18), (Z-19), (Z-20), (Z-21), (Z-22) and (Z-23) form a bond with Linker,

provided that when G is N, Z is one group selected from the group consisting of the formulae (Z-16), (Z-17), (Z-18), (Z-19), (Z-20), (Z-21), (Z-22) and (Z-23),


[Chem. 6-1]




（Z－1）




（Z－2）




（Z－3）



（Z－4）




（Z－5）




（Z－6）


[Chem. 6-2]




（Z－7）




（Z－8）




（Z－9）



（Z－10）




（Z－11）




（Z－12）


[Chem. 6-3]




（Z－13）




（Z－14）




（Z－15）



（Z－16）




（Z－17）




（Z－18）


[Chem. 6-4]




（Z－19）




（Z－20）



（Z－21）



（Z－22）



（Z－23）

each R^{Z1}, which is the same as or different from each other, is optionally substituted $C_{1\text{-}6}$ alkyl, halogen, cyano, -OH, -O-(optionally substituted $C_{1\text{-}6}$ alkyl), -S-(optionally substituted $C_{1\text{-}6}$ alkyl), -NH-(optionally substituted $C_{1\text{-}6}$ alkyl) or -N-(optionally substituted $C_{1\text{-}6}$ alkyl)$_2$,

n is an integer of 0 to 2,

R^{Z2}, R^{Z3} and R^{Z4}, which are the same as or different from each other, are H or optionally substituted $C_{1\text{-}6}$ alkyl,

M is a bond, -O-, -S-, -N(R^M)- or optionally substituted $C_{1\text{-}3}$ alkylene,

R^M is H or optionally substituted $C_{1\text{-}3}$ alkyl,

ring B1 is a benzene ring or a 6-membered hetero ring,

wherein R^{Z1} and Linker form a bond with a carbon atom forming the ring B1, and


ring B2 is a benzene ring or a 5- or 6-membered hetero ring,

wherein M, R^{Z1} and Linker form a bond with a carbon atom forming the ring B2.

[Claim 4]

The compound or a salt thereof according to claim 3, wherein EUB is the formula (XV) below,

[Chem. 7]



(X V)


G is CH or N,

Z is one group selected from the group consisting of the formulae (Z-1), (Z-4), (Z-5), (Z-11), (Z-14), (Z-15), (Z-16), (Z-18), (Z-19), (Z-20), (Z-22) and (Z-23),


wherein ring B1 and ring B2 in the formulae (Z-1), (Z-4), (Z-5), (Z-11), (Z-14), (Z-15), (Z-16), (Z-18), (Z-19), (Z-20), (Z-22) and (Z-23) form a bond with Linker,

provided that when G is N, Z is one group selected from the group consisting of the formulae (Z-16), (Z-18), (Z-19), (Z-20), (Z-22) and (Z-23),


[Chem. 8-1]




（ Z－1 ）




（ Z－4 ）




（ Z－5 ）



（ Z－11 ）




（ Z－14 ）




（ Z－15 ）


[Chem. 8-2]




（Z－16）




（Z－18）




（Z－19）



（Z－20）



（Z－22）



（Z－23）

R^{Z1} is C_{1-6} alkyl or halogen,

n is an integer of 0 or 1,

R^{Z2} and R^{Z4}, which are the same as or different from each other, are H or C_{1-6} alkyl,

M is a bond or C_{1-3} alkylene,

ring B1 is a benzene ring or a pyridine ring,

wherein R^{Z1} and Linker form a bond with a carbon atom forming the ring B1, and

ring B2 is a benzene ring or a pyridine ring,

wherein M, R^{Z1} and Linker form a bond with a carbon atom forming the ring B2.

[Claim 5]

The compound or a salt thereof according to claim 4,

wherein A is CH or N,


Q is CR^Q,

R^Q is C_{3-6} cycloalkyl,

E is CH,

R^1 is the formula (II) below,

[Chem. 9]



(II)

R^{1a} and R^{1c}, which are the same as or different from each other, are C_{1-3} alkyl or halogen,


R^2 is $-V^1-V^2$ or W,

V^1 is a bond, $-CH_2-$, -O-, -S- or $-N(R^{V1})-$,


R^{V1} is C_{1-3} alkyl optionally substituted with one group selected from the group consisting of C_{3-6} cycloalkyl, halogen and -OH,

V^2 is the formula (V-2) or (VI-2) below,

[Chem. 10]




(V-2)




(VI-2)

W is one group selected from the group consisting of the formulae (VII-3), (VII-4), (VIII), (IX), (X), (XI), (XII), (XIII) and (XIV) below,


[Chem. 11]




(VII-3)




(VII-4)




(VIII)




(IX)




(X)




(XI)



(XII)



(XIII)



(XIV)

R^3 is C_{1-6} alkyl optionally substituted with one group selected from the group consisting of -O-(C_{1-6} alkyl), -S-(C_{1-6} alkyl), -N-(C_{1-6} alkyl)$_2$ and heterocycloalkyl or optionally substituted heterocycloalkyl,

X is -O- or -NR^{4X}-,

R^{4X} is C_{1-3} alkyl,

Y^1 is -O-(C_{1-3} alkylene)-^{*Y2} or (C_{1-3} alkylene)-O-^{*Y2} (^{*Y2} represents a linking moiety to Y2),

Y^2 is phenylene or pyridinediyl,

Linker is -(L^1-L^2-L^3-L^4)-,

L^1, L^2, L^3 and L^4, which are the same as or different from each other, are one group selected from the group consisting of a bond, C=O, -O-, -S-, -SO_2-, -NR^L-, acetylene-1,2-diyl, optionally substituted heterocycloalkylene, optionally substituted heteroarylene, saturated 7-membered to 9-membered spiroheterocycloalkylene containing one or two nitrogen atoms, saturated 7-membered to 9-membered bridged heterocycloalkylene

containing two nitrogen atoms and optionally substituted C_{1-6} alkylene, and


RL is H or C_{1-6} alkyl.

[Claim 6]

The compound or a salt thereof according to claim 5,

wherein R^1 is the formula (II) below,

[Chem. 12]



(II)

R^{1a} is halogen, and R^{1c} is C_{1-3} alkyl,


R^2 is $-V^1-V^2$ or W,

V^1 is a bond, -O- or $-N(R^{V1})-$,

R^{V1} is C_{1-3} alkyl,

V^2 is the formula (VI-2) below,

[Chem. 13]



(VI-2)

W is the formula (XII) below,

[Chem. 14]



(XII)

R^3 is C_{1-6} alkyl optionally substituted with one group selected from the group

consisting of -O(C_{1-6} alkyl), oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, oxetanyl, tetrahydrofuranyl or tetrahydropyranyl,

X is -O-,

Y^1 is -O-(C_{1-3} alkylene)-^{*Y2} (^{*Y2} represents a linking moiety to Y^2),

Y^2 is phenylene,

Linker is -(L^1-L^2-L^3-L^4)-,

L^1 is C=O,

L^2 is piperidinediyl optionally substituted with C_{1-3} alkyl, piperazinediyl optionally substituted with C_{1-3} alkyl, pyrrolidinediyl optionally substituted with C_{1-3} alkyl, 3,8-diazabicyclo[3.2.1]octanediyl or 2,6-diazaspiro[3.4]octanediyl,

L^3 is a bond, -N(R^{L3})-, C_{1-3} alkylene or piperazinediyl,


L^4 is a bond, -N(R^{L4})-, -O-, piperazinediyl or C_{1-3} alkylene,

R^{L3} is H or C_{1-3} alkyl,

R^{L4} is H or C_{1-3} alkyl,

EUB is the formula (XV) below,

[Chem. 15]



(XV)

G is CH or N,


Z is one group selected from the group consisting of the formulae (Z-1), (Z-5), (Z-11), (Z-14), (Z-15), (Z-16), (Z-20), (Z-22) and (Z-23),

wherein ring B1 and ring B2 in the formulae (Z-1), (Z-5), (Z-11), (Z-14), (Z-15), (Z-16), (Z-20), (Z-22) and (Z-23) form a bond with Linker,


provided that when G is N, Z is one group selected from the group consisting of the

formulae (Z-16), (Z-20), (Z-22) and (Z-23),


[Chem. 16-1]




（Z－1）




（Z－5）




（Z－11）



（Z－14）




（Z－15）




（Z－16）


[Chem. 16-2]



（Z－20）



（Z－22）



（Z－23）

R^{Z1} is C_{1-3} alkyl or halogen,

n is an integer of 0 or 1,

R^{Z2} is C_{1-3} alkyl,

M is a bond or C_{1-3} alkylene,

ring B1 is a benzene ring or a pyridine ring,

wherein R^{Z1} and Linker form a bond with a carbon atom forming the ring B1, and

ring B2 is a benzene ring or a pyridine ring,

wherein M, R^{Z1} and Linker form a bond with a carbon atom forming the ring B2.

[Claim 7]


The compound or a salt thereof according to claim 6,

wherein Q is CR^{Q},

R^{Q} is cyclopropyl,

R^1 is the formula (II-2) below,

[Chem. 17]




(II-2)

R^2 is $-V^1-V^2$ or W,

V^1 is -O- or $-N(CH_3)-$,

V^2 is the formula (VI-2) below,


[Chem. 18]



(VI-2)

W is the formula (XII) below,

[Chem. 19]



(XII)


R^3 is C_{1-3} alkyl optionally substituted with $-OCH_3$ or tetrahydrofuranyl, tetrahydrofuranyl or tetrahydropyranyl,

Y^1 is -O-(methylene)-^{*Y2} (^{*Y2} represents a linking moiety to Y^2),


Linker is one group selected from the group consisting of the formulae (L-1), (L-2), (L-3), (L-4), (L-5) and (L-7) below,

wherein C=O in the formulae (L-1), (L-2), (L-3), (L-4), (L-5) and (L-7) forms a bond with Y^2,


[Chem. 20]




（L－1）




（L－2）




（L－3）



（L－4）



（L－5）



（L－7）


L' is -O-, -(C_{1-3} alkylene)-NH-, -N(CH_3)(C_{1-3} alkylene)-, piperazinediyl or -(C_{1-3} alkylene)-piperazinediyl,

L" is a bond, C_{1-3} alkylene or -(C_{1-3} alkylene)-O-,

R^{L2} is H or C_{1-3} alkyl,

EUB is the formula (XV) below,

[Chem. 21]



(XV)

G is CH or N, and


Z is one group selected from the group consisting of the formulae (Z-1A), (Z-1B), (Z-5A), (Z-5B), (Z-14A), (Z-14B), (Z-14C), (Z-15A), (Z-16A), (Z-16B), (Z-16C), (Z-16D), (Z-20A), (Z-22A), (Z-23A), (Z-23B), (Z-23C), (Z-23D), (Z-23E) and (Z-23F) below,

wherein a benzene ring or a 6-membered hetero ring in the formulae (Z-1A), (Z-1B),


(Z-5A), (Z-5B), (Z-14A), (Z-14B), (Z-14C), (Z-15A), (Z-16A), (Z-16B), (Z-16C), (Z-16D), (Z-20A), (Z-22A), (Z-23A), (Z-23B), (Z-23C), (Z-23D), (Z-23E) and (Z-23F) form a bond with Linker,

provided that when G is N, Z is one group selected from the group consisting of (Z-16A), (Z-16B), (Z-16C), (Z-16D), (Z-20A), (Z-22A), (Z-23A), (Z-23B), (Z-23C), (Z-23D), (Z-23E) and (Z-23F).


[Chem. 22-1]




（Z－1A）




（Z－1B）




（Z－5A）



（Z－5B）




（Z－14A）




（Z－14B）


[Chem. 22-2]




（Z－14C）




（Z－15A）




（Z－16A）



（Z－16B）




（Z－16C）




（Z－16D）


[Chem. 22-3]




（Z－20A）




（Z－22A）




（Z－23A）




（Z－23B）




（Z－23C）



（Z－23D）



（Z－23E）



（Z－23F）

[Claim 8]


The compound or a salt thereof according to claim 7,

wherein R^2 is $-V^1-V^2$ or W,

V^1 is -O-,

V^2 is the formula (VI-2) below,


[Chem. 23]



(VI-2)

W is the formula (XII) below,

[Chem. 24]




(XII)


R^3 is n-propyl optionally substituted with $-OCH_3$ or tetrahydropyranyl,

Linker is the formula (L-5A) or (L-7A) below.

[Chem. 25]




（L－5A）



（L－7A）

EUB is the formula (XV) below,

[Chem. 26]




(XV)


G is CH or N, and

Z is one group selected from the group consisting of the formulae (Z-1A), (Z-14B), (Z-15A), (Z-16A) and (Z-22A) below,


[Chem. 27]




（Z－1A）




（Z－14B）



（Z－15A）



（Z－16A）



（Z－22A）


wherein a benzene ring or a 6-membered hetero ring in the formulae (Z-1A), (Z-14B), (Z-15A), (Z-16A) and (Z-22A) forms a bond with Linker,

provided that when G is N, Z is (Z-16A) or (Z-22A).

[Claim 9]

The compound or a salt thereof according to claim 2, wherein EUB is the formula (XV) below,

[Chem. 28]



(XV)

G is CR^G or N,


R^G is H or $C_{1\text{-}6}$ alkyl,

Z is one group selected from the group consisting of the formulae (Z-1), (Z-2), (Z-3), (Z-4), (Z-5), (Z-6), (Z-7), (Z-8), (Z-9), (Z-10), (Z-11), (Z-12), (Z-13), (Z-14), (Z-15), (Z-16), (Z-17), (Z-18), (Z-19), (Z-20), (Z-21), (Z-22), (Z-23), (Z-24), (Z-25), (Z-26) and (Z-27) below,


wherein ring B1 and ring B2 in the formulae (Z-1), (Z-2), (Z-3), (Z-4), (Z-5), (Z-6), (Z-7), (Z-8), (Z-9), (Z-10), (Z-11), (Z-12), (Z-13), (Z-14), (Z-15), (Z-16), (Z-17), (Z-18), (Z-19), (Z-20), (Z-21), (Z-22), (Z-23), (Z-24), (Z-25), (Z-26) and (Z-27) form a bond with Linker,

provided that when G is N, Z is one group selected from the group consisting of the formulae (Z-1), (Z-16), (Z-17), (Z-18), (Z-19), (Z-20), (Z-21), (Z-22), (Z-23), (Z-24), (Z-25), (Z-26) and (Z-27),


[Chem. 29-1]




（Z－1）




（Z－2）




（Z－3）



（Z－4）




（Z－5）




（Z－6）


[Chem. 29-2]




（Z－7）




（Z－8）




（Z－9）



（Z－10）




（Z－11）




（Z－12）


[Chem. 29-3]




（Z－13）




（Z－14）




（Z－15）



（Z－16）




（Z－17）




（Z－18）


[Chem. 29-4]




（Z－19）




（Z－20）



（Z－21）




（Z－22）




（Z－23）


[Chem. 29-5]




（Z－24）



（Z－25）



（Z－26）



（Z－27）

each R^{Z1}, which is the same as or different from each other, is optionally substituted $C_{1\text{-}6}$ alkyl, halogen, cyano, -OH, -O-(optionally substituted $C_{1\text{-}6}$ alkyl), -S-(optionally substituted $C_{1\text{-}6}$ alkyl), -NH-(optionally substituted $C_{1\text{-}6}$ alkyl) or -N-(optionally substituted

C_{1-6} alkyl)$_2$,

n is an integer of 0 to 2,

R^{Z2}, R^{Z3}, R^{Z4} and R^{Z5}, which are the same as or different from each other, are H or optionally substituted C_{1-6} alkyl,

M is a bond, -O-, -S-, -N(R^M)- or optionally substituted C_{1-3} alkylene,

R^M is H or optionally substituted C_{1-3} alkyl,

ring B1 is a benzene ring or a 6-membered hetero ring,

wherein R^{Z1} and Linker form a bond with a carbon atom forming the ring B1, and

ring B2 is a benzene ring or a 5- or 6-membered hetero ring,

wherein M, R^{Z1} and Linker form a bond with a carbon atom forming the ring B2.

[Claim 10]

The compound or a salt thereof according to claim 9,


wherein A is CH or N,

Q is CR^Q,

R^Q is cyclopropyl,

R^1 is the formula (II-2) below,

[Chem. 30]




(II-2)

R^2 is -V^1-V^2 or W,

V^1 is -O- or -N(CH_3)-,

V^2 is the formula (VI-2) below,


[Chem. 31]



(VI-2)

W is the formula (VII-4) or (XII) below,

[Chem. 32]



(VII-4) (XII)

R^3 is C_{1-3} alkyl optionally substituted with $-OCH_3$ or tetrahydrofuranyl, tetrahydrofuranyl or tetrahydropyranyl,

X is -O-,


Y^1 is -O-(methylene)-^{*Y2} (^{*Y2} represents a linking moiety to Y^2),

Y^2 is phenylene,


Linker is one group selected from the group consisting of the formulae (L-1), (L-2), (L-3), (L-4), (L-5) and (L-7) below,

wherein C=O in the formulae (L-1), (L-2), (L-3), (L-4), (L-5) and (L-7) forms a bond with Y^2,


[Chem. 33]




（L－1）




（L－2）




（L－3）



（L－4）



（L－5）



（L－7）


L' is -O-, -(C_{1-3} alkylene)-NH-, -N(CH_3)(C_{1-3} alkylene)-, piperazinediyl or -(C_{1-3} alkylene)-piperazinediyl,

L" is a bond, C_{1-3} alkylene or -(C_{1-3} alkylene)-O-,

R^{L2} is H or C_{1-3} alkyl,

EUB is the formula (XV) below,

[Chem. 34]




(XV)


G is CH or N, and

Z is one group selected from the group consisting of the formulae (Z-1A), (Z-1B), (Z-5A), (Z-5B), (Z-14A), (Z-14B), (Z-14C), (Z-15A), (Z-16A), (Z-16B), (Z-16C), (Z-16D), (Z-20A), (Z-22A), (Z-23A), (Z-23B), (Z-23C), (Z-23D), (Z-23E), (Z-23F) and (Z-24A) below,


[Chem. 35-1]




（Z－1A）




（Z－1B）




（Z－5A）



（Z－5B）




（Z－14A）




（Z－14B）


[Chem. 35-2]




（Z－14C）




（Z－15A）




（Z－16A）



（Z－16B）




（Z－16C）




（Z－16D）


[Chem. 35-3]




（Z－20A）




（Z－22A）




（Z－23A）




（Z－23B）




（Z－23C）



（Z－23D）




（Z－23E）



（Z－23F）

[Chem. 35-4]



（Z－24A）

wherein a benzene ring or a 6-membered hetero ring in the formulae (Z-1A), (Z-1B), (Z-5A), (Z-5B), (Z-14A), (Z-14B), (Z-14C), (Z-15A), (Z-16A), (Z-16B), (Z-16C), (Z-16D), (Z-20A), (Z-22A), (Z-23A), (Z-23B), (Z-23C), (Z-23D), (Z-23E) and (Z-23F) form a bond with Linker, and a benzene ring in the formula (Z-24A) forms a bond with Linker,

provided that when G is N, Z is one group selected from the group consisting of (Z-1A), (Z-16A), (Z-16B), (Z-16C), (Z-16D), (Z-20A), (Z-22A), (Z-23A), (Z-23B), (Z-23C),

(Z-23D), (Z-23E), (Z-23F) and (Z-24A).

[Claim 11]

The compound or a salt thereof according to claim 1, wherein the compound of the formula (I) is selected from the group consisting of:

5-[(8-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione,

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione,

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione,

3-[5-({(3S)-4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]-4-{[(3S)-pyrrolidin-3-yl]oxy}quinolin-8-yl]oxy}methyl)benzoyl]-3-methylpiperazin-1-yl}methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]piperidine-2,6-dione,

1-(6-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-1-methyl-1H-indazol-3-yl)-1,3-diazinane-2,4-dione,

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]quinolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione,

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione and

1-(7-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}imidazo[1,2-a]pyridin-3-yl)-1,3-diazinane-2,4-dione.

[Claim 12]

The compound or a salt thereof according to claim 11, wherein the compound is:

5-[(8-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione.

[Claim 13]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione.

[Claim 14]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione.

[Claim 15]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-[5-({(3S)-4-[4-({[(7M)-6-cyclopropyl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]-4-{[(3S)-pyrrolidin-3-yl]oxy}quinolin-8-yl]oxy}methyl)benzoyl]-3-methylpiperazin-1-yl}methyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]piperidine-2,6-dione.

[Claim 16]

The compound or a salt thereof according to claim 11, wherein the compound is:

1-(6-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-1-methyl-1H-indazol-3-yl)-1,3-diazinane-2,4-dione.

[Claim 17]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]quinolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione.

[Claim 18]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione.

[Claim 19]

The compound or a salt thereof according to claim 11, wherein the compound is:

1-(7-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}imidazo[1,2-a]pyridin-3-yl)-1,3-diazinane-2,4-dione.

[Claim 20]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(oxan-4-yl)oxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione n phosphate.

[Claim 21]

The compound or a salt thereof according to claim 11, wherein the compound is:

3-(5-{[(3S)-4-{4-[({(7M)-6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(2S)-2-methoxypropoxy]quinazolin-8-yl}oxy)methyl]benzoyl}-3-methylpiperazin-1-yl]methyl}-3-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-2,6-dione n phosphate.

[Claim 22]

A pharmaceutical composition comprising the compound or a salt thereof according to claim 1 and one or more pharmaceutically acceptable excipients.

[Claim 23]

The pharmaceutical composition according to claim 22, which is a pharmaceutical composition for use in treatment of pancreatic cancer.

[Claim 24]

Use of the compound or a salt thereof according to claim 1 for the manufacture of a pharmaceutical composition for use in treatment of pancreatic cancer.

[Claim 25]

The compound or a salt thereof according to claim 1 for use in treatment of pancreatic cancer.

[Claim 26]

Use of the compound or a salt thereof according to claim 1 for use in treatment of pancreatic cancer.

[Claim 27]

Use of the compound or a salt thereof according to claim 1 in the manufacture of a medicament for treating pancreatic cancer in a subject in need thereof, wherein an effective amount of the compound or salt is to be administered to the subject.